184 related articles for article (PubMed ID: 25316307)
1. Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Renoir T; Argyropoulos A; Chevarin C; Lanfumey L; Hannan AJ
Pharmacol Biochem Behav; 2014 Dec; 127():15-20. PubMed ID: 25316307
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant-Like Effect of the Norepinephrine-Dopamine Reuptake Inhibitor Bupropion in a Mouse Model of Huntington's Disease with Dopaminergic Dysfunction.
Renoir T; Argyropoulos A; Hannan AJ
J Huntingtons Dis; 2012; 1(2):261-6. PubMed ID: 25063334
[TBL] [Abstract][Full Text] [Related]
3. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
[TBL] [Abstract][Full Text] [Related]
4. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease.
Tyebji S; Saavedra A; Canas PM; Pliassova A; Delgado-García JM; Alberch J; Cunha RA; Gruart A; Pérez-Navarro E
Neurobiol Dis; 2015 Feb; 74():41-57. PubMed ID: 25449908
[TBL] [Abstract][Full Text] [Related]
5. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
6. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
[TBL] [Abstract][Full Text] [Related]
7. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
8. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
Johnson MA; Rajan V; Miller CE; Wightman RM
J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
Mo C; Renoir T; Hannan AJ
Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
[TBL] [Abstract][Full Text] [Related]
10. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
Hickey MA; Reynolds GP; Morton AJ
J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA
Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069
[TBL] [Abstract][Full Text] [Related]
12. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation.
Dallérac GM; Vatsavayai SC; Cummings DM; Milnerwood AJ; Peddie CJ; Evans KA; Walters SW; Rezaie P; Hirst MC; Murphy KP
Neurodegener Dis; 2011; 8(4):230-9. PubMed ID: 21282937
[TBL] [Abstract][Full Text] [Related]
13. 'Super-Enrichment' Reveals Dose-Dependent Therapeutic Effects of Environmental Stimulation in a Transgenic Mouse Model of Huntington's Disease.
Mazarakis NK; Mo C; Renoir T; van Dellen A; Deacon R; Blakemore C; Hannan AJ
J Huntingtons Dis; 2014; 3(3):299-309. PubMed ID: 25300333
[TBL] [Abstract][Full Text] [Related]
14. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease.
Spektor BS; Miller DW; Hollingsworth ZR; Kaneko YA; Solano SM; Johnson JM; Penney JB; Young AB; Luthi-Carter R
Brain Res Mol Brain Res; 2002 Jun; 102(1-2):118-28. PubMed ID: 12191502
[TBL] [Abstract][Full Text] [Related]
15. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
16. Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.
Dallérac GM; Cummings DM; Hirst MC; Milnerwood AJ; Murphy KP
Neuromolecular Med; 2016 Mar; 18(1):146-53. PubMed ID: 26782175
[TBL] [Abstract][Full Text] [Related]
17. Loss of the Sexually Dimorphic Neuro-Inflammatory Response in a Transgenic Mouse Model of Huntington's Disease.
Renoir T; Pang TY; Shikano Y; Li S; Hannan AJ
J Huntingtons Dis; 2015; 4(4):297-303. PubMed ID: 26599196
[TBL] [Abstract][Full Text] [Related]
18. Striatal neurochemical changes in transgenic models of Huntington's disease.
Ariano MA; Aronin N; Difiglia M; Tagle DA; Sibley DR; Leavitt BR; Hayden MR; Levine MS
J Neurosci Res; 2002 Jun; 68(6):716-29. PubMed ID: 12111832
[TBL] [Abstract][Full Text] [Related]
19. Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.
Puginier E; Bharatiya R; Chagraoui A; Manem J; Cho YH; Garret M; De Deurwaerdère P
Neurochem Int; 2019 Sep; 128():186-195. PubMed ID: 31054882
[TBL] [Abstract][Full Text] [Related]
20. Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis.
Kennedy L; Shelbourne PF; Dewar D
Brain Res; 2005 Mar; 1039(1-2):14-21. PubMed ID: 15781041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
